Browsing by Author "Hoang, Van T."

Now showing 1 - 3 of 3
  • Thumbnail Image
    Item
    Argonaute 2 Expression Correlates with a Luminal B Breast Cancer Subtype and Induces Estrogen Receptor Alpha Isoform Variation
    (MDPI, 2016-09-21) Conger, Adrienne K.; Martin, Elizabeth C.; Yan, Thomas J.; Rhodes, Lyndsay V.; Hoang, Van T.; La, Jacqueline; Anbalagan, Muralidharan; Burks, Hope E.; Rowan, Brian G.; Nephew, Kenneth P.; Collins-Burow, Bridgette M.; Burow, Matthew E.; Cellular and Integrative Physiology, School of Medicine
    Estrogen receptor alpha (ERα) signaling pathways are frequently disrupted in breast cancer and contribute to disease progression. ERα signaling is multifaceted and many ERα regulators have been identified including transcription factors and growth factor pathways. More recently, microRNAs (miRNAs) are shown to deregulate ERα activity in breast carcinomas, with alterations in both ERα and miRNA expression correlating to cancer progression. In this study, we show that a high expression of Argonaute 2 (AGO2), a translation regulatory protein and mediator of miRNA function, correlates with the luminal B breast cancer subtype. We further demonstrate that a high expression of AGO2 in ERα+ tumors correlates with a poor clinical outcome. MCF-7 breast cancer cells overexpressing AGO2 (MCF7-AGO2) altered ERα downstream signaling and selective ERα variant expression. Enhanced ERα-36, a 36 kDa ERα isoform, protein and gene expression was observed in vitro. Through quantitative polymerase chain reaction (qPCR), we demonstrate decreased basal expression of the full-length ERα and progesterone receptor genes, in addition to loss of estrogen stimulated gene expression in vitro. Despite the loss, MCF-7-AGO2 cells demonstrated increased estrogen stimulated tumorigenesis in vivo. Together with our clinical findings on AGO2 expression and the luminal B subtype, we suggest that AGO2 is a regulator of altered ERα signaling in breast tumors.
  • Thumbnail Image
    Item
    Constitutive activation of MEK5 promotes a mesenchymal and migratory cell phenotype in triple negative breast cancer
    (Impact Journals, 2021-05-18) Matossian, Margarite D.; Hoang, Van T.; Burks, Hope E.; La, Jacqueline; Elliott, Steven; Brock, Courtney; Rusch, Douglas B.; Buechlein, Aaron; Nephew, Kenneth P.; Bhatt, Akshita; Cavanaugh, Jane E.; Flaherty, Patrick T.; Collins-Burow, Bridgette M.; Burow, Matthew E.; Medicine, School of Medicine
    Triple negative breast cancer (TNBC) is an aggressive subtype of breast cancer with limited targeted therapeutic options. A defining feature of TNBC is the propensity to metastasize and acquire resistance to cytotoxic agents. Mitogen activated protein kinase (MAPK) and extracellular regulated kinase (ERK) signaling pathways have integral roles in cancer development and progression. While MEK5/ERK5 signaling drives mesenchymal and migratory cell phenotypes in breast cancer, the specific mechanisms underlying these actions remain under-characterized. To elucidate the mechanisms through which MEK5 regulates the mesenchymal and migratory phenotype, we generated stably transfected constitutively active MEK5 (MEK5-ca) TNBC cells. Downstream signaling pathways and candidate targets of MEK5-ca cells were based on RNA sequencing and confirmed using qPCR and Western blot analyses. MEK5 activation drove a mesenchymal cell phenotype independent of cell proliferation effects. Transwell migration assays demonstrated MEK5 activation significantly increased breast cancer cell migration. In this study, we provide supporting evidence that MEK5 functions through FRA-1 to regulate the mesenchymal and migratory phenotype in TNBC.
  • Thumbnail Image
    Item
    NEK5 activity regulates the mesenchymal and migratory phenotype in breast cancer cells
    (Springer, 2021-08) Matossian, Margarite; Elliott, Steven; Hoang, Van T.; Burks, Hope E.; Wright, Maryl K.; Alzoubi, Madlin; Yan, Thomas; Chang, Tiffany; Wathieu, Henri; Windsor, Gabrielle; Hartono, Alifiani Bo; Lee, Sean; Zuercher, William J.; Drewry, David H.; Wells, Carrow; Kapadia, Nirav; Buechlein, Aaron; Fang, Fang; Nephew, Kenneth P.; Collins-Burow, Bridgette M.; Burow, Matthew E.; Medicine, School of Medicine
    Purpose Breast cancer remains a prominent global disease affecting women worldwide despite the emergence of novel therapeutic regimens. Metastasis is responsible for most cancer-related deaths, and acquisition of a mesenchymal and migratory cancer cell phenotypes contributes to this devastating disease. The utilization of kinase targets in drug discovery have revolutionized the field of cancer research but despite impressive advancements in kinase-targeting drugs, a large portion of the human kinome remains understudied in cancer. NEK5, a member of the Never-in-mitosis kinase family, is an example of such an understudied kinase. Here, we characterized the function of NEK5 in breast cancer. Methods Stably overexpressing NEK5 cell lines (MCF7) and shRNA knockdown cell lines (MDA-MB-231, TU-BcX-4IC) were utilized. Cell morphology changes were evaluated using immunofluorescence and quantification of cytoskeletal components. Cell proliferation was assessed by Ki-67 staining and transwell migration assays tested cell migration capabilities. In vivo experiments with murine models were necessary to demonstrate NEK5 function in breast cancer tumor growth and metastasis. Results NEK5 activation altered breast cancer cell morphology and promoted cell migration independent of effects on cell proliferation. NEK5 overexpression or knockdown does not alter tumor growth kinetics but promotes or suppresses metastatic potential in a cell type-specific manner, respectively. Conclusion While NEK5 activity modulated cytoskeletal changes and cell motility, NEK5 activity affected cell seeding capabilities but not metastatic colonization or proliferation in vivo. Here we characterized NEK5 function in breast cancer systems and we implicate NEK5 in regulating specific steps of metastatic progression.